Decipher testing utilized for treatment of early-stage prostate cancer

Researchers from the Michigan Urological Surgery Improvement Collaborative (MUSIC; MI, USA) have published recent findings in Prostate Cancer and Prostatic Diseases, which demonstrated that Decipher testing – using the 22-gene microarray-based genomic classifier DecipherProstate Biopsy – was valuable in informing treatment decisions for individuals with prostate cancer. Testing biopsies is one method to investigate the status of cancers. However, one study of 855 patients – using data collected between 2015 to 2019 – indicated that biopsies for prostate cancer can be improved by utilizing genomic predictive testing alongside it. In the study, Decipher testing was used to determine each patient’s...